SCHEMBL7877790

SCHEMBL7877790

Cc1cc(OCCCN2CCCC2)cc2[nH]c(C(=O)N(C)C(=N)N)cc12

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.43
PDGFRB P09619 1/20 0.43
KDM4E B2RXH2 6/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 2/20 0.40
HRH3 Q9Y5N1 5/20 0.39
DRD2 P14416 2/20 0.39
DRD3 P35462 2/20 0.39
CHEK2 O96017 1/20 0.38
ALDH1A1 P00352 4/20 0.38
MAOB P27338 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.37
DHODH Q02127 1/20 0.37
HRH1 P35367 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7882048 0.95 FLT3 (0.48) FLT3PDGFRBKDM4EDRD2DRD3
SCHEMBL7873204 0.89 HRH3 (0.42) FLT3KDM4EPOLBHRH3DRD2
SCHEMBL7884754 0.87 HRH3 (0.37) FLT3PDGFRBKDM4ESMN1; SMN2POLB
SCHEMBL7879773 0.87 ULK1 (0.42) FLT3PDGFRBHRH3DRD2CHEK2
SCHEMBL7877848 0.85 MCL1 (0.37) FLT3PDGFRBKDM4EPOLBDRD2
SCHEMBL7881137 0.84 PDGFRB (0.41) FLT3PDGFRBKDM4ESMN1; SMN2CHEK2
Hydrochloric Acid SCHEMBL7877311 0.84 MCL1 (0.37) PDGFRBKDM4EDRD2DRD3
Hydrochloric Acid SCHEMBL8634807 0.84 MCL1 (0.37) PDGFRBKDM4EDRD2DRD3
SCHEMBL7877823 0.84 DRD3 (0.46) FLT3PDGFRBDRD2DRD3
Hydrochloric Acid SCHEMBL7877867 0.84 DRD3 (0.45) FLT3PDGFRBKDM4ESMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed